Cobenfy (KarXT) is an innovative therapeutic drug for schizophrenia, approved in the United States in 2024 and specifically designed for adult patients with schizophrenia. This drug is a fixed-dose combination of xanomeline (a muscarinic agonist) and trospium chloride (a muscarinic antagonist), administered orally in capsule dosage form.

Precautions for Using Cobenfy (KarXT)

Clearly Defined Contraindications

Patients with existing urinary retention.

Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C).

Patients with gastric emptying disorders.

Patients with a history of allergy to Cobenfy or trospium chloride.

Patients with untreated angle-closure glaucoma.

Medication Guidelines for Special Populations

Elderly Patients: The recommended starting dose is 50 mg/20 mg twice daily.

A slower dose escalation schedule should be considered, with the maximum recommended dose being 100 mg/20 mg twice daily.

Studies have shown that the risk of urinary retention is significantly increased in the elderly population, especially in male patients with benign prostatic hyperplasia.

Patients with Hepatic or Renal Impairment

Moderate to severe hepatic impairment is an absolute contraindication.

Use is not recommended in patients with mild hepatic impairment.

Use is contraindicated in patients with moderate to severe renal impairment (eGFR < 60 mL/min).

Patients with mild renal impairment may use the drug according to the standard dosage regimen.

Key Requirements for Administration

The drug must be taken at least 1 hour before a meal or at least 2 hours after a meal.

Opening the capsule shell is strictly prohibited.

Medication Monitoring for Cobenfy (KarXT)

Monitoring of Basic Physiological Indicators

Liver Function Tests: Conduct comprehensive tests of liver enzyme and bilirubin levels.

Heart Rate Monitoring: Establish baseline heart rate data.

Conduct regular rechecks based on clinical indications during treatment.

Medication Adherence Management

Strictly follow the administration frequency of twice daily.

Do not adjust the dose or discontinue the drug without authorization.

Establish a regular medication-taking routine.

Self-Monitoring Guidelines

Signs of Urinary Retention: Difficulty urinating, weakened urine flow, and a feeling of bladder fullness.

Abnormalities of the Hepatobiliary System: Manifestations such as jaundice, abdominal pain, and dark urine.

Symptoms of Allergic Reactions: Symptoms such as facial edema and difficulty breathing require emergency treatment.